Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2954-2970

  Barosi, Giovanni ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL FEATURE; HUMAN; ITALY; MEDICAL INFORMATION; MYELOFIBROSIS; MYELOID METAPLASIA; PHILADELPHIA 1 CHROMOSOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION;

EID: 0032858488     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2954     Document Type: Article

References (190)

1. Heuck G: Zwei Falle von Leukemie mit eigenthumlichen Blutresp. Knokenmarksbefund. Virchows Arch 78:475-481, 1879
2. McNally RJ, Rowland D, Roman E, et al: Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 15:173-189, 1997
3. Najean Y, Dresch C, Rain J-D: The very-long-term course of polycythaemia: A complement to the previously published data of the Polycythemia Vera Study Group. Br J Haematol 86:233-235, 1994
4. Messinezy M, Pearson TC, Prochazka A, et al: Treatment of primary proliferative polycythaemia by venesection and low-dose busulphan: Retrospective study from one centre. Br J Haematol 61:657-666, 1985
5. Bellucci S, Janvier M, Tobelem G, et al: Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58:2440-2447, 1986
6. Jacobson RJ, Salo A, Fialkow PJ: Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194, 1978
7. Reilly JT, Wilson G, Barnett A, et al: Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis. Br J Haematol 88:575-581, 1994
8. Buschle M, Janssen JWG, Drexler H, et al: Evidence of pluripotent stem cell origin of idiopathic myelofibrosis: Clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 2:658-660, 1988
9. Kreipe H, Jaquet K, Felgner J, et al: Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 78:1814-1817, 1991
10. Asimakopoulos FA, Gilbert JGR, Aldred MA, et al: Interstitial deletion constitutes the major mechanism for loss of heterozygosity on chromosome 20q in polycythemia vera. Blood 88:2690-2698, 1996
11. Gilliland DG, Blanchard KL, Levy J, et al: Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci U S A 88:6848-6852, 1991
12. El-Kassar N, Hetet G, Briere J, et al: Clonality analysis of hematopoiesis in essential thombocythemia: Advantage of studying T lymphocytes and platelets. Blood 89:128-134, 1997
13. Tsukamoto N, Morita K, Maehara T, et al: Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: Demonstration of heterogeneity in lineage involvement. Br J Haematol 86:253-258, 1994
14. Chikkappa G, Carsten AL, Chanana AD, et al: Increased ganulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia. Am J Hematol 4:121-131, 1978
15. Eridani S, Dudley JM, Sawyer BM, et al: Erythropoietic colonies in a serum-free system: Results in primary proliferative polycythaemia and thrombocythaemia. Br J Haematol 67:387-391, 1987
16. Carlo-Stella C, Cazzola M, Ganser A, et al: Effect of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70:1014-1019, 1987
17. Battegay EJ, Thomssen C, Nissen C, et al: Endogenous megakaryocyte colonies from peripheral blood in precursor cell cultures of patients with myeloproliferative disorders. Eur J Haematol 42:321-326, 1989
18. Li Y, Hetet G, Maurer AM, et al: Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br J Haematol 87:471-476, 1994
19. Li Y, Hetet G, Kiladjian JJ, et al: Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Haematol 92:60-66, 1996
20. Taksin AL, Le Couedic J-P, Dusanter-Fourt I, et al: Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 93:125-139, 1999
21. Siitnen T, Savolainen ER, Koistinen P: Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes. Leukemia 8:631-637, 1994
22. Nakata Y, Kimura A, Katoh O, et al: c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 91:661-663, 1995
23. Kimura A, Nakata Y, Katoh O, et al: c-kit point mutation in patients with myeloproliferative disorders. Leuk Lymphoma 25:281-287, 1997
24. Le Bousse-Kerdilès M-C, Chevillard S, Charpentier A, et al: Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis with myeloid metaplasia. Blood 88:4534-4546, 1996
25. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 86:419-431, 1995
26. Ku H, Yonemura Y, Kaushansky K, et al: Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice. Blood 87:4544-4551, 1996
27. Carver-Moore K, Broxmeyer HE, Luoh SM, et al: Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 88:803-808, 1996
28. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin receptor by platelets from patients with polycythenia vera. N Engl J Med 338:572-580, 1998
29. Moliterno AR, Spivak JL: Impaired glycosylation of the thrombopoietin receptor in polycythemia vera platelets. Blood 92:488a, 1998 (suppl 1) (abstr)
30. Wang JC, Chen C, Lou L-H, et al: Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia 11:1827-1832, 1997
31. Cohen-Solal K, Villeval JL, Titeux M, et al: Constitutive expression of Mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 88:2578-2584, 1996
32. Yan XQ, Lacey D, Flechter F, et al: Chronic exposure to retroviral encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood 86:4025-4033, 1995
33. Cocault L, Bousacry D, Le Bousse Kerdiles C, et al: Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood 88:1656-1665, 1996
34. Yan XQ, Lacey D, Hill D, et al: A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation. Blood 88:402-409, 1996
35. Villeval J-L, Cohen-Solal K, Tulliez M, et al: High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 11:4369-4383, 1997
36. Frey BM, Rafii S, Teterson M, et al: Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: Insight into the pathophysiology of osteomyelofibrosis. J Immunol 160:691-699, 1998
37. Abina MA, Tulliez M, Lacout C, et al: Major effects of TPO delivered by a single injection of recombinant adenovirus on prevention of septicemia and anemia associated with myelosuppression in mice: Risk of sustained expression inducing myelofibrosis due to immunosuppression. Gene Ther 5:497-506, 1998
38. Wendung F, Varlet P, Charon M, et al: MPLV: A retrovirus complex inducing an acute myeloproliferative leukemia disorder in adult mice. Virology 149:242-246, 1986
39. Reilly JT, Snowden JA, Spearing RL, et al: Cytogentic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br J Haematol 98:96-102, 1997
40. Juneau AL, Kaehler M, Christensen ER, et al: Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. Cancer Genet Cytogenet 103:117-123, 1998
41. Pastore C, Nomdedeu J, Volpe G, et al: Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders. Genes Chromosom Cancer 14:106-111, 1995
42. La Starza R, Wlodarska I, Aventin A, et al: Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood 91:231-237, 1998
43. Gaidano G, Guerrasio A, Serra A, et al: Molecular mechanisms of tumor progression in chronic myeloproliferative disorders. Leukemia 8:S27-S29, 1994 (suppl 1)
44. Wang JC, Chen C: N-RAS oncogene mutations in patients with agnogenic myeloid metaplasia in leukemic transformation. Leuk Res 22:639-243, 1998
45. Castro-Malaspina H: Pathogenesis of myelofibrosis: Role of ineffective megakaryocytopoiesis and megakaryocyte components, in Berk PD, Castro-Malaspina H, Wasserman LR (eds): Myelofibrosis and the Biology of Connective Tissue. New York, NY, Alan R. Liss Inc, 1984, pp 427-454
46. Dalley A, Smith JM, Reilly JT, et al: Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: Evidence for a role of extracellular calmodulin in fibroblast proliferation. Br J Haematol 93:856-862, 1996
47. Martyré M-C, Le Bousse-Kerdiles M-C, Romquin N, et al: Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97:441-448, 1997
48. Eastham JM, Reilly JT, Mac Neil S: Raised urinary calmodulin levels in idiopathic myelofibrosis: Possible implications for the etiology of fibrosis. Br J Haematol 86:668-670, 1994
49. Yanagida M, We Y, Imai A, et al: The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 99:739-745, 1997
50. Kimura A, Katoh O, Hyodo H, et al: Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 72:486-491, 1989
51. Terui T, Nitsu Y, Mahara K, et al: The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75:1540-1548, 1990
52. Martyré M-C, Magdelenat H, Bryckaert MC, et al: Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis and myeloid metaplasia. Br J Haematol 77:80-86, 1991
53. Rameshwar P, Chang VT, Thacker UF, et al: Systemic transforming growth factor-beta in patients with bone marrow fibrosis: Pathophysiological implications. Am J Hematol 59:133-142, 1998
54. Rosen DM, Stempien SA, Thompson AY, et al: Transforming growth factor-beta modulates the expression of osteoblast and chondroblast phenotypes in vitro. J Cell Physiol 134:337-346, 1988
55. Roberts AB, Sporn MB, Assoian RK, et al: Transforming growth factor b regulates primitive murine hematopoetic cell proliferation. Blood 75:596-602, 1990
56. Rameshwar P, Chang VT, Gascon P: Implication of CD44 in adhesion-mediated overproduction of TGF-beta and IL-1 in monocytes from patients with bone marrow fibrosis. Br J Haematol 93:22-29, 1996
57. Gilbert HS, Praloran V, Stanley ER: Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: Association with myeloid metaplasia and peripheral bone marrow extension. Blood 74:1231-1234, 1989
58. Rameshwar P, Denny TN, Stein D, et al: Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: Potential role for interleukin-1 and TGF-beta. J Immunol 153:2819-2830, 1994
59. Partanen S, Ruutu T, Vuopio P: Circulating haematopoietic progenitors in myelofibrosis. Scand J Haematol 29:325-330, 1982
60. Wang JC, Cheung CP, Ahmed F, et al: Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis. Br J Haematol 54:301-307, 1983
61. Douer D, Fabian I, Cline MJ: Circulating pluripotent haemopietic cells in patients with myeloprolferative disorders. Br J Haematol 54:373-381, 1983
62. Hibbin JA, Njoku OS, Matutes E, et al: Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 57:495-503, 1984
63. Douay L, Laporte JP, Lefrancois G, et al: Blood and spleen hematopoiesis in patients with myelofibrosis. Leuk Res 11:725-730, 1987
64. Han ZC, Brière J, Nedellec G, et al: Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur J Haematol 40:130-135, 1988
65. Andreasson B, Swolin B, Kutti J: Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol 59:171-176, 1997
66. Pereira A, Cervantes F, Brugues R, et al: Bone marrow histopathology in primary myelofibrosis: Clinical and hematologic correlations and prognostic evaluation. Eur J Haematol 44:95-99, 1990
67. Wilkins BS, Green A, Wild AE, et al: Extramedullary haemopoiesis in fetal and adult human spleen: A quantitative immunohistological study. Histopathology 24:241-247, 1994
68. Wolf BC, Neiman RS: Myelofibrosis with myeloid metaplasia: Pathophysiologic implications of the correlations between bone marrow changes and progression of splenomegaly. Blood 65:803-809, 1985
69. Thiele J, Wagner S, Bertsch HP, et al: Pro-megakaryoblast in bone marrow tissue from patients with primary (idiopathic) osteomyelofibrosis (agnogenic myelod metaplasia): An immunomorphometric study on trephine biopsies. Pathol Res Pract 186:589-596, 1990
70. Thiele J, Klein H, Falk S, et al: Splenic megakaryocytopoiesis in primary (idiopathic) osteomyelofibrosis: An immunohistological and morphometric study with comparison of corresponding bone marrow features. Acta Haematol 87:176-180, 1992
71. Porcu P, Neiman RS, Orazi A: Splenectomy in agnogenic myeloid metaplasia. Blood 93:2132-2133, 1999
72. Ward HP, Block MH: The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine 50:357-420, 1971
73. Varki A, Lottenberg R, Griffith R, et al: The syndrome of idiopathic myelofibrosis: A clinicopathologic review with emphasis on the prognostic variables predicting survival. Medicine (Baltimore) 62:353-371, 1983
74. Barosi G, Berzuini C, Liberato LN, et al: A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70:397-401, 1988
75. Hasselbalch H: Idiopathic myelofibrosis: A clinical study of 80 patients. Am J Hematol 34:291-300, 1990
76. Visani G, Finelli C, Castelli U, et al: Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4-9, 1990.
77. Rupoli S, Da Lio L, Sisti S, et al: Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 68:205-212, 1994.
78. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 88:1013-1018, 1996
79. Tefferi A, Silverstein MN: Agnogenic myeloid metaplasia. Cancer Invest 15:177-179, 1997
80. Kvasnicka HM, Thiele J, Werden C, et al: Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 80:708-719, 1997
81. Ozen S, Ferhanoglu B, Senocak M, et al: Idiopathic myelofibrosis (agnogenic myeloid metaplasia): Clinicopathological analysis of 32 patients. Leuk Res 2:125-131, 1997
82. Cervantes F, Pereira A, Esteve J, et al: Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635-640, 1997
83. Cervantes F, Pereira A, Esteve J, et al: Idiopathic myelofibrosis: Initial features, evolutive patterns and survival in a series of 106 patients. Med Clin (Barc) 109:651-655, 1997
84. Barosi G, Ambrosetti A, Centra A, et al: Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 91:3630-3636, 1998
85. Cervantes F, Barosi G, Demory J-L, et al: Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102:684-690, 1998
86. Morel P, Demory JL, Dupriez B: Relevance of prognostic features in myeloid metaplasia to selection of patients for bone marrow transplantation. Blood 89:2219-2228, 1997
87. Boxer LA, Camitta BM, Berenberg W, et al: Myelofibrosis-myeloid melaplasia in childhood. Pediatrics 55:861-865, 1975
88. Mallouh AA, Rahman SA: Agnogenic myeloid metaplasia in children. Am J Dis Child 146:965-967, 1992
89. Sekhar M, Prentice HG, Popat U, et al: Idiopathic myelofibrosis in children. Br J Haematol 93:349-397, 1996
90. Sahu S, Shah SS, Srivastava A, et al: Pediatric hyperfibrotic myelodysplasia: An unusual clinicopathologic entity. Pediatr Hematol Oncol 14:133-139, 1997
91. Sieff CA, Malleson P: Familial myelofibrosis. Arch Dis Child 55:888-893, 1980
92. Bonduel M, Sciuccati G, Torres AF, et al: Familial idiopathic myelofibrosis and multiple hemangiomas. Am J Hematol 59:175-177, 1998
93. Cervantes F, Pereira A, Esteve J, et al: The changing profile of idiopathic myelofibrosis: A comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 60:101-105, 1998
94. Barosi G, Cazzola M, Frassoni F, et al: Erythropoiesis in myelofibrosis with myeloiod metaplasia: Recognition of different classes of patients by erythrokinetics. Br J Haematol 48:263-272, 1981
95. Bentley SA, Murray KH, Lewis SM, et al: Erythroid hypoplasia in myelofibrosis: A feature associated with blast transformation. Br J Haematol 36:41-47, 1977
96. Barosi G, Baraldi A, Cazzola M, et al: Red cell aplasia in myelofibrosis with myeloid metaplasia: A distinct functional and clinical entity. Cancer 52:1290-1296, 1983
97. Howarth JE, Waters HM, Hyde K, et al: Detection of erythroid hypoplasia in myelofibrosis using erythrokinetic studies. J Clin Pathol 42:1250-1252, 1989
98. Pettit JE, Lewis SM, Nicholas AW: Transitional myeloproliferative disorders. Br J Haematol 43:167-184, 1979
99. Imam TH, Doll DC: Acute cardiac tamponade associated with pericardial extramedullary hematopoiesis in agnogenic myeloid metaplasia. Acta Haematol 98:42-43, 1997
100. Xiao JC, Walz-Mattmuller R, Ruck P, et al: Renal involvement in myeloproliferative disorders: A study of autopsy cases. Gen Diagn Pathol 142:147-153, 1997
101. Patel BM, Su WP, Perniciaro C, et al: Cutaneous extramedullary hematopoiesis. J Am Acad Dermatol 32:805-807, 1995
102. Bartlett RP, Greipp PR, Tefferi A, et al: Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 70:1161-1164, 1995
103. Yusen RD, Kollef MH: Acute respiratory failure due to extramedullary hematopoiesis. Chest 108:1170-1172, 1995
104. Cook G, Sharp RA: Spinal cord compression due to extramedullary hematopoiesis in myelofibrosis. J Clin Pathol 47:464-465, 1994
105. Khumbanonda M, Horowitz HI, Eyster ME: Coombs' positive hemolytic anemia in myelofibrosis with myeloid metaplasia. Am J Med Sci 258:89-93, 1969
106. Bernhardt B, Valletta M: Lupus anticoagulant in myelofibrosis. Am J Med Sci 272:229-231, 1976
107. Lewis CM, Pegrum GD: Immune complexes in myelofibrosis: A possible guide to management. Br J Haematol 39:233-239, 1978
108. Caligaris Cappio F, Vigliani R, Novarino A, et al: Idiopatic myelofibrosis: A possible role for immune-complexes in the pathogenesis of bone marrow fibrosis. Br J Haematol 49:17-21, 1981
109. Gordon BR, Coleman M, Kohen P, et al: Immunological abnormalities in myelofibrosis with activation of the complement system. Blood 58:904-910, 1981
110. Rondeau E, Solal-Celigny P, Dhermy D, et al: Immune disorders in agnogenic myeloid metaplasia: Relations to myelofibrosis. Br J Haematol 53:467-475, 1983
111. Caughman W, Stern R, Haynes H: Neutrophilic dermatosis in myeloproliferative disorders: Atypical forms of pyoderma gangrenosum and Seet's syndrome associated with myeloproliferative disorders. J Am Acad Dermatol 9:751-758, 1983
112. Hasselbalch H, Berild D, Paaske-Hansen O: Platelet associated IgG and IgM in myelofibrosis. Scand J Haematol 32:488-492, 1984
113. Soppi E, Nousiainen T, Seppa A, et al: Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: A report of three cases and a review of the literature. Br J Haematol 73:43-47, 1989
114. Loewy G, Mathew A, Distenfel A: Skin manifestation of agnogenic myeloid metaplasia. Am J Hematol 45:167-170, 1994
115. Wang JC, Wang A: Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. Br J Haematol 86:380-382, 1994
116. Buyssens N, Bourgeois NH: Chronic myelocytic leukemia versus idiopathic myelofibrosis: A diagnostic problem in bone marrow biopsies. Cancer 40:1548-1561, 1977
117. Sutan C, Scoazec JY, Imbert M: Histopathologie de la Moelle Osseuse. Paris, France, Masson, 1991
118. Thile J, Chen YS, Kvasnicka HM, et al: Evolution of fibroosteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis: A histomorphometric study on sequential trephine biopsies. Leuk Lymphoma 14:163-169, 1994
119. Thiele J, Kvasnicka HM, Fischer R, et al: Clinicopathological impact of the interaction between megakaryocytes and myeloid stroma in chronic myeloproliferative disorders: A concise update. Leuk Lymphoma 24:463-481, 1997
120. Georgii A, Vykoupil KF, Buhr T, et al: Chronic myeloproliferative disorders in bone marrow biopsies. Pathol Res Pract 186:3-27, 1990
121. Dickstein JI, Vardamin JW: Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol 99:513-525, 1993
122. Laszlo J: Myeloproliferative disorders (MPD): Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 2:409-432, 1975
123. Kouides PA, Bennett JM: Morphology and classification of the myelodysplastic syndromes and their pathologic variants. Semin Hematol 33:95-110, 1996
124. Verhoef GE, De Wolf-Peeters C, Ferrant A, et al: Myelodysplastic syndromes with bone marrow fibrosis: A myelodysplastic disorder with proliferative features. Ann Hematol 63:235-241, 1991
125. Pagliuca A, Layton DM, Manoharan A, et al: Myelofibrosis in primary myelodysplastic syndromes: A clinico-morphological study in 10 cases. Br J Haematol 71:499-504, 1989
126. Storniolo AM, Moloney WC, Rosenthal DS, et al: Chronic myelomonocytic leukemia. Leukemia 4:766-770, 1990
127. Barosi G, Buratti A, Costa A, et al: An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 68:2310-2318, 1991
128. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
129. Bennett JM, Catovsky D, Daniel MT, et al: The chronic myeloid leukemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemiaProposal by the French-American-British Cooperative Leukemia Group. Br J Haematol 87:746-754, 1994
130. Pearson TC, Messinezy M: The diagnostic criteria of polycythemia rubra vera. Leuk Lymphoma 22:87-93, 1996(suppl 1)
131. Michiels JJ, Juvonen E: Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 23:339-347, 1997
132. Murphy S, Peterson P, Iland H, et al: Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39, 1997
133. Thiele J, Kvasnicka HM, Diehl V, et al: Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from the bone marrow. Leuk Lymphoma 33:207-218, 1999
134. Georgii A, Vykoupil KF, Thiele J: Chronic megakaryocytic granulocytic myelosis-CMGM: A subtype of chronic myeloid leukemia. Virchows Arch Pathol Anat 389:253-268, 1980
135. Barosi G, Liberato LN, Grossi A, et al: The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 104:730-737, 1999
136. Rozman C, Giralt M, Feliu E, et al: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991
137. Njoku OS, Lewis SM, Catowsky D, et al: Anaemia in myelofibrosis: Its value in prognosis. Br J Haematol 54:79-89, 1983
138. Besa EC, Nowell PC, Geller NL, et al: Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival. Cancer 49:308-313, 1982
139. Reilly JT, Snowden JA, Spearing RL, et al: Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: A study of 106 cases. Br J Haematol 98:96-102, 1997
140. Kimura A, Kawaishi K, Nakata Y, et al: Leukemic transformation of primary myelofibrosis: Immunophenotype, genotype and growth characteristics of blast cells. Leuk Lymphoma 19:493-498, 1995
141. Dokal I, Jones L, Deenmamode M, et al: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 71:158-160, 1989
142. Schmitz N, Suttorp M, Schlegelberger B, et al: The role of the spleen after bone marrow transplantation of primary myelofibrosis. Br J Haematol 81:616-618, 1992
143. Ifrah N, Gardembas-Pain M, Hunault M, et al: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 73:575-576, 1989
144. Anderson JE, Appelbaum FR, Chauncev TR, et al: Allogeneic bone marrow transplantation (BMT) for polycythemia vera (PV), agnogenic myeloid metaplasia (AMM), and essential thrombocytosis (ET): A series of 13 patients. Blood 86:388a, 1995 (suppl 1) (abstr)
145. de-Revel T, Giraudier S, Nedellec G, et al: Allogeneic bone marrow transplantation for postpolycythemic myeloid metaplasia with myelofibrosis: A case report. Bone Marrow Transplant 16:187-189, 1995
146. Bandini G, Ljugman PL, Arcese G, et al: Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 3:105, 1994 (suppl)
147. Creemers GJ, Loewenberg B, Hagenbeek A: Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol 82:772-773, 1992
148. Przepiorka D, Giralt S, Khouri I, et al: Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases. Am J Hematol 57:24-28, 1998
149. Guardiola P, Esperou H, Cazals-Hatem D, et al: Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia: French Society of Bone Marrow Transplantation. Br J Haematol 98:1004-1009, 1997
150. Guardiola P, Anderson JE, Bandini G, et al: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe; Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93:2831-2838, 1999
151. Hast R, Engsyedt L, Jameson S, et al: Oxymetolone treatment in myelofibrosis. Blut 37:19-26, 1978
152. Barosi G, Liberate NL, Guarnone R: Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 83:365-369, 1993
153. Rodriguez JN, Martino ML, Dieguez JC, et al: rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia: Experience in 6 patients and meta-analytical approach. Haematologica 83:616-621, 1998
154. Ware RE, Hanft VN, Pickens CV, et al: Acquired DNA mutations and the leukemogenic potential of hydroxyurea therapy. Blood 92:424a, 1998 (suppl 1) (abstr)
155. Manoharan A: Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 77:252-254, 1991
156. Wickramashinghe SN, Peart S, Gill DS: Alpha-interferon in primary idiopathic myelofibrosis. Lancet ii:1524-1525, 1987
157. Bevan PC, Bateman CJT: Interferon-alpha for idiopathic myelo fibrosis. Lancet i:766, 1988 (letter)
158. Furesi L, Laghi Pasini F, et al: Interferon alpha-2b in the treatment of myelofibrosis. Haematologica 75:587-589, 1990
159. Dalla KP, Zeigler ZR, Shadduck RK: Alpha-interferon in myelofibrosis: A case report. Br J Haematol 86:654-656, 1994
160. Nakamura F, Andoh A, Minamiguchi H, et al: A case of interstitial pneumonitis associated with natural alpha-interferon therapy for myelofibrosis. Acta Haematol 97:222-224, 1997
161. Kikawa Y, Fukumoto Y, Obata K, et al: Successful treatment of essential thrombocythemia evolving into agnogeneic myeloid metaplasia with interferon-alpha. J Pediatr Hematol Oncol 20:464-466, 1998
162. Domingues MA, Haepers AT, Massaut IH, et al: Reversal of bone marrow fibrosis in idiopathic myelofibrosis after treatment with alpha-interferon. Haematologica 83:1124-1125, 1998
163. Parmeggiani L, Ferrant A, Bodhain JL, et al: Alpha-interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur J Haematol 39:228-232, 1987
164. Hasselbalch H: Interferon in myelofibrosis. Lancet i:355, 1988 (letter) (erratum appears in Lancet 1(8587):720, 1988)
165. Seewann HL, Gastl G, Lang A, et al: Interferon-alpha-2 in the treatment of idiopathic myelofibrosis. Blut 56:161-163, 1988
166. Turri D, Mitra ME, Di Trapani R, et al: Alpha interferon in primary myelofibrosis. Haematologica 74:417-418, 1989
167. Tichelli A, Gratwohl A, Berger C, et al: Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a. Blut 58:15-19, 1989
168. Gisslinger H, Ludwig H, Linkesch W, et al: Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet i:634-639, 1989
169. Lazzarino M, Vitale A, Morra E: Interferon alpha as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br J Haematol 72:173-177, 1989
170. Barosi G, Liberato NL, Costa A, et al: Cytoreductive effect of recombinant alfa-interferon in patients with myelofibrosis with myeloid metaplasia. Haematologica 75:48-50, 1990 (suppl 4)
171. McCarthy D, Clark J, Giles F: The treatment of myelofibrosis with alpha-interferon. Br J Haematol 78:590-591, 1991
172. Craig JIO, Antony RS, Parker AC: Circulating progenitor cells in myelofibrosis: The effect of recombinant alpha-2b interferon in vivo and in vitro. Br J Haematol 78:155-160, 1991
173. Yataganas X, Meletis J, Plata E, et al: Alpha interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer 27:S69-S71, 1991 (suppl 4)
174. List AF, Doll DC: Alpha-interferon in the treatment of idiopathic myelofibrosis. Br J Haematol 80:566-567, 1992
175. Cervantes F, Alcorta I, Escoda L, et al: Alpha interferon treatment of idiopathic myelofibrosis. Med Clin (Barc) 101:498-500, 1993
176. Gilbert HS: Long term treatment of myeloproliferative disease with interferon-alpha-2b: Feasibility and efficacy. Cancer 15:1205-1213, 1998
177. Barosi G, Ambrosetti A, Buratti A, et al: Splenectomy for patients with myelofibrosis with myeloid metaplasia: Pretreatment variables and outcome prediction. Leukemia 7:200-206, 1993
178. Mesa RA, Nagorney DM, Silverstein MN, et al: Splenectomy in myelofibrosis with myeloid metaplasia (MMM): A single institution experience with 223 patients. Blood 92:489a, 1998 (suppl 1) (abstr)
179. Chaffanjon PC, Brichon PY, Ranchoup Y: Portal vein thrombosis following splenectomy for hematologic disease: Retrospective study with Doppler color flow imaging. World J Surg 22:1082-1086, 1998
180. Loring LA, Panicek DM, Karpeh MS: Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: Is routine surveillance imaging necessary? J Comput Assist Tomogr 22:856-860, 1998
181. Lafaye F, Rain JD, Clot P, et al: Risks and benefits of splenectomy in myelofibrosis: An analysis of 39 cases. Nouv Rev Fr Hematol 36:359-362, 1994
182. Linet MS, Nyren O, Gridley G, et al: Risk of cancer following splenectomy. Int J Cancer 66:611-616, 1996
183. Robinette CD, Fraumeni JF Jr: Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet 2:127-129, 1977
184. Nason-Burchenal K, Wolff L: Involvement of the spleen in preleukemic development of a murine retrovirus-induced promonocytic leukemia. Cancer Res 52:5317-5322, 1992
185. Moloney WC, King VP: Reduction of leukemia incidence following splenectomy in the rat. Cancer Res 33:573-574, 1973
186. Tefferi A, Silverstein MN, Li CY: 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99:352-357, 1997
187. Oertel MD: Anagrelide, a selctive thrombocytopenic agent. Am J Health Syst Pharm 55:1979-1986, 1998
188. Elliott MA, Chen MG, Silverstein, et al: Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103:505-511, 1998
189. Sciascia R, Mazza P, Tondi L: Splenic irradiation in the treatment of idiopathic myelofibrosis: Retrospective study of 14 cases. Radiol Med 76:87-90, 1988
190. Wagner H Jr, McKeough PG, Desforges J, et al: Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia: Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Cancer 58:1204-1207, 1986